Calidad de vida y función sexual en mujeres con disfunción del piso-pélvico del sur de Chile

Antecedentes/Objetivos: La disfunción del piso pélvico (DPP) es muy prevalente, afectando a un tercio de las mujeres adultas. Estas patologías no suponen un riesgo vital, pero sus síntomas pueden interferir con las actividades de la vida diaria incluyendo aspectos físicos, sociales y sexuales. En el sur de Chile, en el Hospital de alta complejidad (Regional-Concepción), se ha implementado la Unidad de Piso Pélvico (UPP). No hay evidencia sobre el efecto que supone en la calidad de vida y la función sexual de las mujeres que la padecen Describir la calidad de vida y función sexual de mujeres controladas en la Unidad de Piso Pélvico de un Hospital de alta complejidad en Chile. Métodos: Estudio transversal. Población: usuarias con DPP de la UPP del H. Regional-Concepción. Muestra 173. Variables: Caract. sociodemográficas, antecedentes obstétricos, tipo de DPP, Variables de Calidad de Vida (percepción del estado de salud, limitación emocional, limitación de actividades cotidianas, alteraciones de actividades sociales) (Short Form-12 Health Survey) y función sexual (PISQ-12). Análisis: medidas de dispersión, frecuencia absoluta- relativa. Resultados: Edad media 57 años, 88% con ingreso menor a 357€. 91% con IMC-sobrepeso y obesidad, 64% ≥ 3 hijos. Tipos DPP: 53% incontinencia de orina (IO), 35% prolapso vaginal (Pp), 12% IO+Pp. Calidad de vida (n = 173): Mala percepción de salud: 95%. Limitación emocional: 37%. Limitación de actividades cotidianas: 67%. Alteraciones de actividades sociales: 57% Función sexual (n = 95): Disfunción alta: 8,4%, moderada: 41,1%, baja 50,5%. El 15% nunca tuvo deseo-sexual los últimos 6 meses. El 14% admite no haber alcanzado el orgasmo en los últimos 6 meses, el mismo porcentaje admite no sentir excitación en el mismo período. El 19% admite no estar satisfechas con las actividades sexuales actuales, el 15% siente dolor durante las relaciones sexuales, el 40% admite sufrir de pérdidas de orina durante la actividad sexual, y el mismo número admite restringir su vida sexual debido al miedo de pérdida de orina durante el acto sexual. El 27% admite tener reacciones emocionales negativas durante las relaciones sexuales. El 10% y el 13% admite que sus parejas sufrían de disfunción eréctil y eyaculación, respectivamente. Por último, el 42% de las mujeres admite que sus orgasmos en los últimos 6 meses son más intensos. Conclusiones: Las mujeres con DPP presentan una alteración negativa de su calidad de vida y de su función sexual, aunque existe cierta incongruencia al valorar positivamente la calidad de los orgasmos cuando los demás aspectos de la vida sexual son negativos

Molecular Blocking of CD23 Supports Its Role in the Pathogenesis of Arthritis

BACKGROUND: CD23 is a differentiation/activation antigen expressed by a variety of hematopoietic and epithelial cells. It can also be detected in soluble forms in biological fluids. Initially known as the low-affinity receptor for immunoglobulin E (Fc epsilonRII), CD23 displays various other physiologic ligands such as CD21, CD11b/c, CD47-vitronectin, and mannose-containing proteins. CD23 mediates numerous immune responses by enhancing IgE-specific antigen presentation, regulating IgE synthesis, influencing cell differentiation and growth of both B- and T-cells. CD23-crosslinking promotes the secretion of pro-inflammatory mediators from human monocytes/macrophages, eosinophils and epithelial cells. Increased CD23 expression is found in patients during allergic reactions and rheumatoid arthritis while its physiopathologic role in these diseases remains to be clarified. METHODOLOGY/PRINCIPAL FINDINGS: We previously generated heptapeptidic countrestructures of human CD23. Based on in vitro studies on healthy and arthritic patients' cells, we showed that CD23-specific peptide addition to human macrophages greatly diminished the transcription of genes encoding inflammatory cytokines. This was also confirmed by significant reduction of mediator levels in cell supernatants. We also show that CD23 peptide decreased IgE-mediated activation of both human and rat CD23(+) macrophages. In vivo studies in rat model of arthritis showed that CD23-blocking peptide ameliorates clinical scores and prevent bone destruction in a dose dependent manner. Ex-vivo analysis of rat macrophages further confirmed the inhibitory effect of peptides on their activation. Taken together our results support the role of CD23 activation and subsequent inflammatory response in arthritis. CONCLUSION: CD23-blocking peptide (p30A) prevents the activation of monocytes/macrophages without cell toxicity. Thus, targeting CD23 by antagonistic peptide decreases inflammatory markers and may have clinical value in the treatment of human arthritis and allergic reactions involving CD23

Promoción de la salud y entornos saludables

A forestar forestalAplicación de un programa educativo participativo en salud  bucal a una comunidad de adultos mayoresBiblioteca móvil y su implementación en el hospital Padre HurtadoConsumo de riesgo de alcohol en Chile: una propuesta innovadora de intervenciónDiseño de un programa interactivo de promoción de la salud vocal para NB1Encuentro formativo en promoción de salud y gestión de entornos saludables para TenoExperiencia docente: programa intersectorial de promoción/prevención en preescolares de comunas vulnerables, Región MetropolitanaFiltrado glomerular, método preventivo aparición de fibrosis sistémica nefrogénica por gadolinio en examen de RMImplementación de consejerías en vida sana en APS, Región de los RíosMedicina preventiva en feria libre de la población San Gregorio: Cecof San Gregorio, Contagiando SaludMetodología innovadora en la enseñanza de una ectoparasitosisPrevención de accidentes por monóxido de carbono en edificios, Providencia 2002-2009Programa de promoción y prevención en salud bucal para preescolaresPromoviendo hábitos saludables en los vecinos de Reñaca Alto, Viña del Mar, 2009Rol de la capacitación en la implementación de acciones para la prevención de la obesidadSatisfacción usuaria en el Cesfam Natales a un año de su funcionamientoTres estrategias publicitarias y de comunicación aplicadas al consumo de alcohol de bajo riesgoTropa de la salud: uso de los medios como forma de promover la salu

In vivo biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary drug delivery

AbstractThe development of clinically acceptable albumin-based nanoparticle formulations for use in pulmonary drug delivery has been hindered by concerns about the toxicity of nanomaterials in the lungs combined with a lack of information on albumin nanoparticle clearance kinetics and biodistribution. In this study, the in vivo biocompatibility of albumin nanoparticles was investigated following a single administration of 2, 20, and 390μg/mouse, showing no inflammatory response (TNF-α and IL-6, cellular infiltration and protein concentration) compared to vehicle controls at the two lower doses, but elevated mononucleocytes and a mild inflammatory effect at the highest dose tested. The biodistribution and clearance of 111In labelled albumin solution and nanoparticles over 48h following a single pulmonary administration to mice was investigated by single photon emission computed tomography and X-ray computed tomography imaging and terminal biodistribution studies. 111In labelled albumin nanoparticles were cleared more slowly from the mouse lung than 111In albumin solution (64.1±8.5% vs 40.6±3.3% at t=48h, respectively), with significantly higher (P<0.001) levels of albumin nanoparticle-associated radioactivity located within the lung tissue (23.3±4.7%) compared to the lung fluid (16.1±4.4%). Low amounts of 111In activity were detected in the liver, kidneys, and intestine at time points >24h indicating that small amounts of activity were cleared from the lungs both by translocation across the lung mucosal barrier, as well as mucociliary clearance. This study provides important information on the fate of albumin vehicles in the lungs, which may be used to direct future formulation design of inhaled nanomedicines

DNA methylation and cancer incidence: lymphatic–hematopoietic versus solid cancers in the Strong Heart Study

Background Epigenetic alterations may contribute to early detection of cancer. We evaluated the association of blood DNA methylation with lymphatic–hematopoietic cancers and, for comparison, with solid cancers. We also evaluated the predictive ability of DNA methylation for lymphatic–hematopoietic cancers. Methods Blood DNA methylation was measured using the Illumina Infinium methylationEPIC array in 2324 Strong Heart Study participants (41.4% men, mean age 56 years). 788,368 CpG sites were available for differential DNA methylation analysis for lymphatic–hematopoietic, solid and overall cancers using elastic-net and Cox regression models. We conducted replication in an independent population: the Framingham Heart Study. We also analyzed differential variability and conducted bioinformatic analyses to assess for potential biological mechanisms. Results Over a follow-up of up to 28 years (mean 15), we identified 41 lymphatic–hematopoietic and 394 solid cancer cases. A total of 126 CpGs for lymphatic–hematopoietic cancers, 396 for solid cancers, and 414 for overall cancers were selected as predictors by the elastic-net model. For lymphatic–hematopoietic cancers, the predictive ability (C index) increased from 0.58 to 0.87 when adding these 126 CpGs to the risk factor model in the discovery set. The association was replicated with hazard ratios in the same direction in 28 CpGs in the Framingham Heart Study. When considering the association of variability, rather than mean differences, we found 432 differentially variable regions for lymphatic–hematopoietic cancers. Conclusions This study suggests that differential methylation and differential variability in blood DNA methylation are associated with lymphatic–hematopoietic cancer risk. DNA methylation data may contribute to early detection of lymphatic–hematopoietic cancers